Kathryn A Ellis1, Cassandra Szoeke2, Ashley I Bush3, David Darby3, Petra L Graham4, Nicola T Lautenschlager1, S Lance Macaulay5, Ralph N Martins6, Paul Maruff7, Colin L Masters3, Simon J McBride5, Kerryn E Pike8, Stephanie R Rainey-Smith6, Alan Rembach3, Joanne Robertson3, Christopher C Rowe9, Greg Savage4, Victor L Villemagne3, Michael Woodward10, William Wilson5, Ping Zhang5, David Ames1. 1. Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne; St. Vincent's Aged Psychiatry Service, St George's Hospital, Kew, Victoria, Australia. 2. National Ageing Research Institute (NARI), Parkville, Victoria, Australia. 3. Florey Institute of Neuroscience and Mental Health (MHRI), Parkville, Victoria, Australia. 4. Macquarie University, Sydney, NSW, Australia. 5. Commonwealth Scientific and Industrial Research Organisation, Preventative Health Flagship, CMSE CMIS (CSIRO), Parkville, Victoria, Australia. 6. Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia. 7. CogState Limited, Melbourne, Victoria, Australia. 8. Latrobe University, Melbourne, Victoria, Australia. 9. Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia. 10. Austin Health, Aged Care, Heidelberg, Victoria, Australia.
Abstract
BACKGROUND: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing is a prospective study of 1,112 individuals (211 with Alzheimer's disease (AD), 133 with mild cognitive impairment (MCI), and 768 healthy controls (HCs)). Here we report diagnostic and cognitive findings at the first (18-month) follow-up of the cohort. The first aim was to compute rates of transition from HC to MCI, and MCI to AD. The second aim was to characterize the cognitive profiles of individuals who transitioned to a more severe disease stage compared with those who did not. METHODS: Eighteen months after baseline, participants underwent comprehensive cognitive testing and diagnostic review, provided an 80 ml blood sample, and completed health and lifestyle questionnaires. A subgroup also underwent amyloid PET and MRI neuroimaging. RESULTS: The diagnostic status of 89.9% of the cohorts was determined (972 were reassessed, 28 had died, and 112 did not return for reassessment). The 18-month cohort comprised 692 HCs, 82 MCI cases, 197 AD patients, and one Parkinson's disease dementia case. The transition rate from HC to MCI was 2.5%, and cognitive decline in HCs who transitioned to MCI was greatest in memory and naming domains compared to HCs who remained stable. The transition rate from MCI to AD was 30.5%. CONCLUSION: There was a high retention rate after 18 months. Rates of transition from healthy aging to MCI, and MCI to AD, were consistent with established estimates. Follow-up of this cohort over longer periods will elucidate robust predictors of future cognitive decline.
BACKGROUND: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing is a prospective study of 1,112 individuals (211 with Alzheimer's disease (AD), 133 with mild cognitive impairment (MCI), and 768 healthy controls (HCs)). Here we report diagnostic and cognitive findings at the first (18-month) follow-up of the cohort. The first aim was to compute rates of transition from HC to MCI, and MCI to AD. The second aim was to characterize the cognitive profiles of individuals who transitioned to a more severe disease stage compared with those who did not. METHODS: Eighteen months after baseline, participants underwent comprehensive cognitive testing and diagnostic review, provided an 80 ml blood sample, and completed health and lifestyle questionnaires. A subgroup also underwent amyloid PET and MRI neuroimaging. RESULTS: The diagnostic status of 89.9% of the cohorts was determined (972 were reassessed, 28 had died, and 112 did not return for reassessment). The 18-month cohort comprised 692 HCs, 82 MCI cases, 197 ADpatients, and one Parkinson's disease dementia case. The transition rate from HC to MCI was 2.5%, and cognitive decline in HCs who transitioned to MCI was greatest in memory and naming domains compared to HCs who remained stable. The transition rate from MCI to AD was 30.5%. CONCLUSION: There was a high retention rate after 18 months. Rates of transition from healthy aging to MCI, and MCI to AD, were consistent with established estimates. Follow-up of this cohort over longer periods will elucidate robust predictors of future cognitive decline.
Authors: Anders Wallin; Arto Nordlund; Michael Jonsson; Karin Lind; Åke Edman; Mattias Göthlin; Jacob Stålhammar; Marie Eckerström; Silke Kern; Anne Börjesson-Hanson; Mårten Carlsson; Erik Olsson; Henrik Zetterberg; Kaj Blennow; Johan Svensson; Annika Öhrfelt; Maria Bjerke; Sindre Rolstad; Carl Eckerström Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Piers Johnson; Luke Vandewater; William Wilson; Paul Maruff; Greg Savage; Petra Graham; Lance S Macaulay; Kathryn A Ellis; Cassandra Szoeke; Ralph N Martins; Christopher C Rowe; Colin L Masters; David Ames; Ping Zhang Journal: BMC Bioinformatics Date: 2014-12-08 Impact factor: 3.169
Authors: Paul A Adlard; Bob A Tran; David I Finkelstein; Patricia M Desmond; Leigh A Johnston; Ashley I Bush; Gary F Egan Journal: Front Neurosci Date: 2014-10-31 Impact factor: 4.677
Authors: Emma Lawrence; Carolin Vegvari; Alison Ower; Christoforos Hadjichrysanthou; Frank De Wolf; Roy M Anderson Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Christopher Fowler; Stephanie R Rainey-Smith; Sabine Bird; Julia Bomke; Pierrick Bourgeat; Belinda M Brown; Samantha C Burnham; Ashley I Bush; Carolyn Chadunow; Steven Collins; James Doecke; Vincent Doré; Kathryn A Ellis; Lis Evered; Amir Fazlollahi; Jurgen Fripp; Samantha L Gardener; Simon Gibson; Robert Grenfell; Elise Harrison; Richard Head; Liang Jin; Adrian Kamer; Fiona Lamb; Nicola T Lautenschlager; Simon M Laws; Qiao-Xin Li; Lucy Lim; Yen Ying Lim; Andrea Louey; S Lance Macaulay; Lucy Mackintosh; Ralph N Martins; Paul Maruff; Colin L Masters; Simon McBride; Lidija Milicic; Madeline Peretti; Kelly Pertile; Tenielle Porter; Morgan Radler; Alan Rembach; Joanne Robertson; Mark Rodrigues; Christopher C Rowe; Rebecca Rumble; Olivier Salvado; Greg Savage; Brendan Silbert; Magdalene Soh; Hamid R Sohrabi; Kevin Taddei; Tania Taddei; Christine Thai; Brett Trounson; Regan Tyrrell; Michael Vacher; Shiji Varghese; Victor L Villemagne; Michael Weinborn; Michael Woodward; Ying Xia; David Ames Journal: J Alzheimers Dis Rep Date: 2021-06-03
Authors: Anders Wallin; Arto Nordlund; Michael Jonsson; Kaj Blennow; Henrik Zetterberg; Annika Öhrfelt; Jacob Stålhammar; Marie Eckerström; Mårten Carlsson; Erik Olsson; Mattias Göthlin; Johan Svensson; Sindre Rolstad; Carl Eckerström; Maria Bjerke Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Lutz Frölich; Oliver Peters; Piotr Lewczuk; Oliver Gruber; Stefan J Teipel; Hermann J Gertz; Holger Jahn; Frank Jessen; Alexander Kurz; Christian Luckhaus; Michael Hüll; Johannes Pantel; Friedel M Reischies; Johannes Schröder; Michael Wagner; Otto Rienhoff; Stefanie Wolf; Chris Bauer; Johannes Schuchhardt; Isabella Heuser; Eckart Rüther; Fritz Henn; Wolfgang Maier; Jens Wiltfang; Johannes Kornhuber Journal: Alzheimers Res Ther Date: 2017-10-10 Impact factor: 6.982
Authors: Victor L Villemagne; Christopher C Rowe; Kevin J Barnham; Robert Cherny; Michael Woodward; Svetlana Bozinosvski; Olivier Salvado; Pierrick Bourgeat; Keyla Perez; Christopher Fowler; Alan Rembach; Paul Maruff; Craig Ritchie; Rudy Tanzi; Colin L Masters Journal: Alzheimers Dement (N Y) Date: 2017-11-09